Engaged in research and development of oncology drugs for nearly 20 years with extensive training in both basic science and clinical medicine; Experienced in global clinical development of biologic and small molecules in both solid and blood malignancies. Former Executive Medical Director at Celgene USA; Former Group Medical Director at BMS
Jeffery Lin／Director,Preclinical Drug R&D
Leads 3DMed bio-marker discovery Former Senior scientist of GSK, responsible for drug screening assay, with rich research experience in epigenetics and leukemia Ph.D in Biochemistry and Molecular Bioloy from Chinese Academy of Sciences, Post-Doc from the Chinese Academy of Science Institute of Health
Haolan Lu／Executive Director,Biometrics
Over 14 years of oncology drug development experience with a proven track of success in immuno-oncology pioneering drugs: Opdivo and Yervoy. Former non-small cell lung cancer indication statistical lead of Bristol-Myers Squibb Company, led registration global approvals for Opdivo in the second and third line treatment of NSCLC PH.D. in Biostatistics from University of Minnesota.
Richard Xue／Executive Director,Clinical Operation
More than 17 years industry experience in drug development including work with hospital, clinical research organisations and biopharmaceutical companies. Previous position span a range of functions, including clinical monitoring,BD,Chang Mangament,training and project management, most recently as global trial lead at Celgene oversaw a successful pivotal trail resulting in globals NDA submissions.